Compass Financial Management LLC Acquires New Position in Omeros Corporation $OMER

Compass Financial Management LLC acquired a new position in shares of Omeros Corporation (NASDAQ:OMER) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 32,815 shares of the biopharmaceutical company’s stock, valued at approximately $312,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its position in shares of Omeros by 16.0% in the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 800 shares during the last quarter. State of Wyoming acquired a new position in Omeros in the 4th quarter valued at about $25,000. AQR Capital Management LLC boosted its stake in shares of Omeros by 7.2% during the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 1,532 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Omeros by 12.1% during the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 1,637 shares in the last quarter. Finally, Cerity Partners LLC raised its position in shares of Omeros by 6.1% in the fourth quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company’s stock valued at $523,000 after buying an additional 1,750 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Omeros

In other news, CAO David J. Borges sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the chief accounting officer directly owned 5,906 shares in the company, valued at $111,918.70. This trade represents a 62.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Peter B. Cancelmo sold 25,000 shares of Omeros stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the transaction, the vice president directly owned 200 shares in the company, valued at $3,708. This represents a 99.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 95,906 shares of company stock worth $1,780,205 over the last ninety days. 10.50% of the stock is owned by insiders.

Omeros Stock Performance

Shares of OMER stock opened at $18.95 on Tuesday. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of 14.80 and a beta of 2.60. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65. The company has a 50 day moving average price of $13.70 and a 200 day moving average price of $12.34.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. As a group, equities analysts forecast that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on OMER shares. HC Wainwright restated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Weiss Ratings raised Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.